SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:umu-142300"
 

Search: onr:"swepub:oai:DiVA.org:umu-142300" > Repeated intermitte...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Repeated intermittent ulipristal acetate in the treatment of uterine fibroids : a cost-effectiveness analysis

Geale, Kirk (author)
Umeå universitet,Medicin,PAREXEL International, Stockholm, Sweden,Department of Public Health and Clinical Medicine, Umeå University, Umeå, Sweden
Saridogan, Ertan (author)
Womens Health Division, University College London Hospital, London, UK
Lehmann, Matthieu (author)
PregLem SA, Geneva, Switzerland
show more...
Arriagada, Pablo (author)
PregLem SA, Geneva, Switzerland
Hultberg, Marcus (author)
PAREXEL International, Stockholm, Sweden
Henriksson, Martin (author)
Linköpings universitet,Avdelningen för hälso- och sjukvårdsanalys,Medicinska fakulteten
show less...
 (creator_code:org_t)
DOVE MEDICAL PRESS LTD, 2017
2017
English.
In: ClinicoEconomics and Outcomes Research. - : DOVE MEDICAL PRESS LTD. - 1178-6981. ; 9, s. 669-676
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • There are limited treatment options available for women with moderate to severe symptoms of uterine fibroids (UFs) who wish to avoid surgery. For these women, treatment with standard pharmaceuticals such as contraceptives is often insufficient to relieve symptoms, and patients may require surgery despite their wish to avoid it. Clinical trials demonstrate that ulipristal acetate 5 mg (UPA) is an effective treatment for this patient group, but its cost-effectiveness has not been assessed in this population. A decision-analytic model was developed to simulate a cohort of patients in this population under treatment with UPA followed by surgery as needed compared to treatment with iron and non-steroidal anti-inflammatory drug (NSAID) followed by surgery as needed (best supportive care, BSC). The analysis took the perspective of the National Health Service (NHS) in England, UK, and was based on the published UPA clinical trials. Results were calculated for the long-term costs and quality-adjusted life years (QALYs) for each treatment arm and combined into an incremental cost-effectiveness ratio (ICER) as the primary outcome. The impact of parameter uncertainty on the results was assessed using scenario, deterministic, and probabilistic sensitivity analyses. The results show that treating patients with the UPA strategy, instead of the BSC strategy, results in an additional cost of 1,115 pound and a gain of 0.087 QALYs, resulting in an ICER of 12,850 pound. Given commonly accepted cost-effectiveness thresholds in England, the use of UPA as a repeated, intermittent treatment for women with moderate to severe symptoms of UF wishing to avoid surgery is likely to be a cost-effective intervention when compared to BSC.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Hälsovetenskap -- Hälso- och sjukvårdsorganisation, hälsopolitik och hälsoekonomi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Health Sciences -- Health Care Service and Management, Health Policy and Services and Health Economy (hsv//eng)

Keyword

uterine fibroids
cost-effectiveness
health economics
ulipristal acetate
economic evaluation

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view